MCI and ENA Studies |
|
(FAIRFAX, VA - March 15, 1999) -- Two large-scale studies on possible methods to prevent Alzheimer's disease are initiating recruitment drives. The first is the National Institute on Aging's (NIA) "Memory Impairment Study," which is being launched today. The NIA study is the first step in the Alzheimer's Disease Prevention Initiative, made possible by the increased funding that Congress provided last year -- funding largely made possible by the advocacy efforts of the Alzheimer's Association. NIA's nationwide recruitment is the first large-scale research study to determine whether it is possible to prevent or delay the onset of Alzheimer's disease by treating people with mild cognitive impairment (MCI). MCI is characterized primarily by memory problems, but not dementia. The project seeks to recruit approximately 720 men and women, aged 55-90, with an obvious memory problem, but no other cognitive impairment. Study participants are asked to commit for three years. Sixty to eighty centers across the United States and Canada are participating in the study. The Alzheimer's Disease Cooperative Study at the University of California, San Diego is sponsoring this trial, which is funded by the National Institute on Aging. The second is an international study to access the value of the drug rivastigmine (also known as Exelon or ENA-713) in preventing Alzheimer's disease. This study is also a three-year long trial. Approximately 50 medical centers in Europe, North and South America will conduct the trial.
In the Northern Virginia Chapter Service Area, for more information about these studies please contact the Chapter's telephone Helpline at 703-359-4440 or 800-207-8679. Outside Northern Virginia, please contact your local Chapter.
Last updated: March 25, 1999
Please return to https://www.alz-nova.org or
© 1997, 1998 & 1999 Alzheimer's Association, Northern Virginia Chapter. All rights reserved. |